Insider Transactions for Amylyx Pharmaceuticals, Inc.

Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals, Inc., reported a sale of 7,947 shares of Common Stock on September 10, 2026, at a weighted average price of $32.2139 per share. This transaction, which occurred at prices ranging from $31.76 to $32.68, was to cover tax withholding obligations related to the vesting of performance stock units. The sale was automatic and not at her discretion. Following this transaction, she owns 280,145 shares. Additionally, on the same date, Ms. Bedrosian reported another sale of 2,081 shares of Common Stock at a weighted average price of $33.0919 per share, with prices ranging from $32.85 to $33.29. This transaction was also to cover tax withholding obligations. Post-transaction, her ownership is 278,064 shares. Both transactions were automatic and not discretionary.